Metabolism

Jardiance Alternatives Depend on Why You Take It

Label evidence links heart failure and kidney protection to specific SGLT2 inhibitors while glucose control permits broader medication classes.

For heart failure or kidney disease, the closest label match to Jardiance is Farxiga. In the guides we publish here, alternatives depend on why the medication was prescribed. A licensed healthcare provider must evaluate and decide any prescription change. Invokana, Steglatro, and Brenzavvy lack a heart failure indication. When blood sugar control is the sole treatment goal, older therapies like metformin and glucagon-like peptide-1 (GLP-1) receptor agonists provide distinct labeled routes with different safety considerations. Our Jardiance vs Farxiga page lines up the two labels, while our guides on metformin alternatives and Ozempic vs metformin review other blood sugar therapies.

Jardiance Alternatives at a Glance

In our comparison of Jardiance alternatives, we lined up the prescribing information from FDA labels updated through 2026, alongside published federal pricing documents. The appropriate substitute depends on the specific medical diagnosis your doctor is treating. Heart failure is a labeled use of Jardiance and Farxiga. Invokana, Steglatro, Brenzavvy, metformin and the GLP-1 labels do not list it.

MedicationDrug ClassPrimary Labeled IndicationsAdministration Route
Jardiance (empagliflozin)SGLT2 inhibitorHeart failure, CKD progression risk, T2D CV death reduction, glycemic controlOral daily tablet
Farxiga (dapagliflozin)SGLT2 inhibitorHeart failure, CKD progression risk, T2D HF hospitalization reduction, glycemic controlOral daily tablet
Invokana (canagliflozin)SGLT2 inhibitorT2D MACE reduction, diabetic nephropathy with albuminuria, glycemic controlOral daily tablet
Steglatro (ertugliflozin)SGLT2 inhibitorGlycemic control in type 2 diabetes onlyOral daily tablet
Brenzavvy (bexagliflozin)SGLT2 inhibitorGlycemic control in type 2 diabetes onlyOral daily tablet
Ozempic (semaglutide)GLP-1 receptor agonistGlycemic control, T2D MACE reduction, T2D CKD progression reductionSubcutaneous weekly injection
Rybelsus (oral semaglutide)GLP-1 receptor agonistGlycemic control, T2D MACE reduction in high-risk adultsOral daily tablet
Trulicity (dulaglutide)GLP-1 receptor agonistGlycemic control, T2D MACE reduction with CVD or multiple risk factorsSubcutaneous weekly injection
MetforminOral diabetes drugGlycemic control in type 2 diabetes onlyOral daily tablet

Clinical trials for these separate medications were conducted independently under distinct protocols, patient criteria, and follow-up periods. Because trial results reflect separate clinical programs rather than direct comparative trials, outcome rates cannot be compared directly across products. Your prescriber must assess your kidney function, cardiovascular health, and tolerance before selecting any therapy.

What Jardiance Is Approved For

Jardiance carries four distinct FDA-approved indications covering metabolic, renal, and cardiovascular conditions. The official prescribing information, revised in January 2026, authorizes empagliflozin to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. It is also approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. In adults with type 2 diabetes and established cardiovascular disease, Jardiance is approved to reduce the risk of cardiovascular death. It is also approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes.

The label specifies limitations of use. Empagliflozin is not recommended for glycemic control in patients with type 1 diabetes due to an increased risk of ketoacidosis. It is also not recommended for glycemic control in adults with type 2 diabetes whose eGFR is below 30 mL/min/1.73 m2. For chronic kidney disease, Jardiance is not recommended in patients with polycystic kidney disease, those requiring ongoing or recent intravenous immunosuppressive therapy, or individuals receiving prednisone-equivalent doses above 45 mg daily. Weight loss is not an approved indication for Jardiance, as body weight changes appear in the label as clinical trial observations.

Other SGLT2 Inhibitors: Farxiga, Invokana, Steglatro, Brenzavvy

When seeking alternatives within the SGLT2 inhibitor class, Farxiga provides the closest match to Jardiance's clinical profile. Farxiga's prescribing label was revised in June 2026. Farxiga is approved to treat heart failure in adults to reduce cardiovascular death, heart failure hospitalization, and urgent heart failure visits. It is also approved for adults with chronic kidney disease at risk of progression. For adults with type 2 diabetes and cardiovascular disease or multiple risk factors, it reduces heart failure hospitalization. Farxiga is also approved for glycemic control in adults and children 10 years and older. Unlike Jardiance, Farxiga does not carry a specific indication for reducing cardiovascular death in type 2 diabetes patients without heart failure. Farxiga is not recommended for glycemic control when eGFR falls below 45 mL/min/1.73 m2. Invokana holds a narrower label revised in June 2026. Invokana is indicated for glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes. Its cardiovascular approval is specifically to reduce major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with type 2 diabetes and established cardiovascular disease. Invokana reduces end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and heart failure hospitalization, but this indication is limited to adults with type 2 diabetes and diabetic nephropathy with urinary albumin excretion exceeding 300 mg daily. Invokana has no general heart failure approval, and glycemic use is not recommended when eGFR is under 30 mL/min/1.73 m2. Steglatro and Brenzavvy are limited to glycemic management. Steglatro's sole indication is improving glycemic control in adults with type 2 diabetes, and its label was revised in June 2026. In the VERTIS CV trial reported in Steglatro's label, the hazard ratio for MACE was 0.97, demonstrating non-inferiority to placebo without establishing cardiovascular benefit, and it is not recommended with an eGFR below 45 mL/min/1.73 m2. Brenzavvy, also revised in June 2026, is approved for glycemic control in adults with type 2 diabetes, was not superior to placebo in reducing MACE in its cardiovascular trial, and is not recommended when eGFR falls below 30 mL/min/1.73 m2.

Generic Dapagliflozin and Empagliflozin Availability

On April 7, 2026, the Food and Drug Administration approved the first generic dapagliflozin tablets from multiple generic drug applicants. The approved indications for generic dapagliflozin are limited compared to brand-name Farxiga. The FDA announcement confirmed generic dapagliflozin tablets are approved only to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, and as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Generic dapagliflozin labeling carries the same contraindications, warnings, and precautions as brand Farxiga. Chronic kidney disease and heart failure indications for patients without diabetes were not included in the FDA generic approval announcement. As of November 2, 2026, a DailyMed search for empagliflozin returned only brand products (Jardiance, Glyxambi, Synjardy, Synjardy XR, Trijardy XR) and repackagers. No generic empagliflozin label is currently listed. A prescriber decides any change.

GLP-1 Drugs and Metformin: Labeled Uses and Warnings

When patients and prescribers evaluate non-SGLT2 options for type 2 diabetes, GLP-1 receptor agonists and metformin represent distinct drug classes. Metformin is a generic oral medication indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes. Metformin carries no FDA-approved indications for heart failure, chronic kidney disease progression, or cardiovascular outcomes.

Metformin carries a prominent boxed warning for lactic acidosis. Reported postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, severe hypotension, and resistant bradyarrhythmias. Metformin is contraindicated in patients with severe renal impairment whose eGFR is below 30 mL/min/1.73 m2, initiation is not recommended with an eGFR between 30 and 45 mL/min/1.73 m2, and clinicians must assess benefits and risks if filtration falls below 45 mL/min/1.73 m2. Common adverse reactions in clinical trials included diarrhea in 53% of patients compared to 12% on placebo, and nausea or vomiting in 26% compared to 8%. Approximately 7% of trial participants experienced serum vitamin B12 decreases to subnormal levels, prompting label recommendations for periodic B12 monitoring.

In contrast, GLP-1 receptor agonists provide glycemic control and specific cardiovascular risk protections. Ozempic is injected subcutaneously once weekly, initiating at 0.25 mg weekly for 4 weeks before increasing to 0.5 mg, with a maximum dose of 2 mg weekly. Ozempic is indicated for glycemic control in adults with type 2 diabetes, to reduce MACE in adults with type 2 diabetes and established cardiovascular disease, and to reduce sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Rybelsus provides an oral tablet formulation of semaglutide taken once daily in the morning with up to 4 ounces of plain water, requiring a 30-minute wait before consuming food, beverages, or other oral medications. Rybelsus is indicated for glycemic control and MACE reduction in high-risk adults with type 2 diabetes. Trulicity is a once-weekly subcutaneous injection approved for glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes, and to reduce MACE in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Mounjaro is a weekly subcutaneous injection starting at 2.5 mg and titrating up to 15 mg weekly in adults. Mounjaro is indicated for glycemic control in adults with type 2 diabetes. Ozempic, Rybelsus, Trulicity, and Mounjaro each carry a boxed warning for the risk of thyroid C-cell tumors based on rodent findings. Ozempic and Trulicity are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Unlike SGLT2 inhibitors, GLP-1 labels do not warn of mycotic genital infections or Fournier's gangrene, but warn of pancreatitis and gastrointestinal events.

What Jardiance Costs and Where Generics Stand

The Boehringer Ingelheim pricing page reports the official list price for a 30-day supply of Jardiance is $350.00 as of January 1, 2026. Boehringer Ingelheim also maintains general product information on its patient support portal.

For patients with commercial health insurance, the manufacturer reports that approximately 94% pay between $0 and $50 per month, while the remaining 6% pay an average of $230 monthly. Eligible commercially insured patients may utilize a manufacturer Savings Card to pay as little as $0 for a 30-day to 90-day prescription under program terms and conditions. For patients enrolled in Medicare Part D, manufacturer data indicates approximately 84% pay between $0 and $50 per month, while 16% pay an average of approximately $166 monthly. Beneficiaries receiving Extra Help pay an average of $5.10 to $12.65 per month. The manufacturer notes Medicaid copays average $0 to $10 monthly, Veterans Affairs coverage averages $11 per 30-day supply, and the Boehringer Cares Foundation provides free medication to qualifying individuals.

Under the Inflation Reduction Act, the Centers for Medicare & Medicaid Services published a negotiated price fact sheet and an accompanying CMS pricing infographic establishing the first-cycle maximum fair price for Jardiance. The negotiated price is $197.00 for a 30-day supply, effective January 1, 2026. This negotiated rate represents a 66% discount from the baseline 2023 CMS list price of $573.00 for diabetes, heart failure, and chronic kidney disease indications. $197.00 is the rate Medicare pays and Part D plans must honor. It is not a patient copay. Patient out-of-pocket obligations continue to depend on individual Part D benefit phases and plan formularies.

Who This Is Not For, and What Would Change Our Answer

These medications are not suitable for every clinical situation. The Jardiance label states it is not recommended for glycemic control in type 1 diabetes due to ketoacidosis risk. Talk with your prescriber about any change. For glycemic control, Jardiance, Invokana, and Brenzavvy are not recommended, and metformin is contraindicated, when eGFR falls below 30 mL/min/1.73 m2.

Ozempic and Trulicity are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Rybelsus and Mounjaro carry the same boxed warning for thyroid C-cell tumors. The labels for Jardiance and Farxiga do not recommend use for chronic kidney disease in polycystic kidney disease or with current or recent immunosuppressive therapy for kidney disease. The label lists hypersensitivity to empagliflozin or its excipients as a contraindication.

Our answer would change if a generic empagliflozin label appears on DailyMed. It would also change if a generic dapagliflozin label adds the heart-failure and chronic kidney disease indications, or if your prescriber changes the treatment goal.

Our Takeaway on Jardiance Alternatives

If you take Jardiance for heart failure or kidney disease, the label evidence points to staying within SGLT2 inhibitors with those indications. For glucose control alone, metformin and GLP-1 drugs provide the other documented therapeutic routes. Based on our reading of the FDA labels, the manufacturer pricing page, and the CMS price sheet, the choice between these medications turns on approved clinical uses and kidney-function limits on each product label.

Because alternative-drug pricing was not collected, direct cost comparisons apply only to Jardiance and its Medicare negotiated benchmark. The appropriate clinical choice changes if a generic empagliflozin label appears or if your prescriber modifies your treatment goals. Bring your kidney labs and this table to your prescriber and ask which Jardiance alternatives match your approved uses, or start with our assessment.

Frequently Asked Questions

What is a cheaper substitute for Jardiance?

A cheaper substitute depends on your diagnosis and insurance coverage. Generic metformin is an oral alternative for type 2 diabetes glycemic control, but it carries a boxed warning for lactic acidosis and lacks heart failure or kidney disease indications. For heart failure hospitalization risk in type 2 diabetes, the FDA approved the first generic dapagliflozin tablets in April 2026, though generic dapagliflozin is not approved for chronic kidney disease or heart failure without diabetes. DailyMed listed no generic empagliflozin label as of November 2, 2026. Consult your prescriber and pharmacist to determine covered options under your specific plan.

How much will Jardiance cost in 2026 with Medicare?

Under the Inflation Reduction Act, the CMS first-cycle negotiated price for a 30-day supply of Jardiance is $197.00, effective January 1, 2026. This negotiated rate represents a 66% discount from the 2023 CMS baseline list price of $573.00. $197.00 is the rate Medicare pays and Part D plans must honor. It is not a patient copay. Manufacturer data indicates about 84% of Medicare Part D patients pay between $0 and $50 monthly, while patients with Extra Help pay an average of $5.10 to $12.65 per month.

What is Farxiga approved to treat?

Based on its June 2026 label, Farxiga has four approved uses. It reduces cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure. It reduces sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. It reduces heart failure hospitalization in adults with type 2 diabetes and established cardiovascular disease or risk factors. It also improves glycemic control in adults and children aged 10 and older with type 2 diabetes.

Does Jardiance cause weight loss?

The label lists weight loss only as a trial observation, not an indication. The label shows a 3.1 kg reduction compared to weight gain on glimepiride at Week 104 as a trial observation, but the drug is authorized for heart failure, chronic kidney disease, cardiovascular death risk reduction in type 2 diabetes, and glycemic management.

Topic updates

Get the weekly metabolic health roundup

Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.

No spam. Unsubscribe anytime.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.

Check Where You Stand

Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results

Related Comparisons

← Back to Metabolic Health

See more related comparisons